April 1970
Volume 9, Issue 4
Free
Articles  |   April 1970
The Cataractogenic Effect of Dibromomannitol in Rats
Author Affiliations
  • LUDWIG VON SALLMANN
    Ophthalmology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, United States Department of Health, Education, and Welfare Bethesda, Md., 20014
  • PATRICIA GRIMES
    Ophthalmology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, United States Department of Health, Education, and Welfare Bethesda, Md., 20014
Investigative Ophthalmology & Visual Science April 1970, Vol.9, 291-299. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      LUDWIG VON SALLMANN, PATRICIA GRIMES; The Cataractogenic Effect of Dibromomannitol in Rats. Invest. Ophthalmol. Vis. Sci. 1970;9(4):291-299.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Dibromomannitol (DBM) is one of the new chemotherapeutic compounds beneficial in the treatmentof chronic myelogenous leukemia. Investigation of the effects of the drug on the rat lens has demonstrated that it exerts a complex cytotoxic action on the epithelial population and, with prolonged administration, is cataractogenic in normal animals. The response to DBM only partially resembles that evoked by Myleran, a related drug known to induce cataracts in rats.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×